ATE323482T1 - Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten - Google Patents
Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheitenInfo
- Publication number
- ATE323482T1 ATE323482T1 AT00948576T AT00948576T ATE323482T1 AT E323482 T1 ATE323482 T1 AT E323482T1 AT 00948576 T AT00948576 T AT 00948576T AT 00948576 T AT00948576 T AT 00948576T AT E323482 T1 ATE323482 T1 AT E323482T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- eye diseases
- mapk inhibitors
- mapk
- mitogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14234199P | 1999-07-02 | 1999-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE323482T1 true ATE323482T1 (de) | 2006-05-15 |
Family
ID=22499482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00948576T ATE323482T1 (de) | 1999-07-02 | 2000-06-30 | Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten |
Country Status (9)
Country | Link |
---|---|
US (1) | US20030078274A1 (de) |
EP (1) | EP1196167B1 (de) |
JP (1) | JP2003503456A (de) |
AT (1) | ATE323482T1 (de) |
AU (1) | AU777275B2 (de) |
CA (1) | CA2373883A1 (de) |
DE (1) | DE60027431T2 (de) |
ES (1) | ES2260033T3 (de) |
WO (1) | WO2001001986A1 (de) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100850812B1 (ko) * | 2000-10-23 | 2008-08-06 | 스미스클라인 비참 코포레이션 | 신규 화합물 |
AR035971A1 (es) | 2001-05-16 | 2004-07-28 | Cephalon Inc | Metodos para el tratamiento y la prevencion del dolor |
WO2002100433A1 (en) * | 2001-06-11 | 2002-12-19 | Takeda Chemical Industries, Ltd. | Medicinal compositions |
EP1709965A3 (de) | 2001-07-11 | 2006-12-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methode zur Behandlung von zytokinvermittelten Erkrankungen |
CA2454976C (en) * | 2001-07-26 | 2011-05-10 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient |
AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
UA80295C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
WO2004064733A2 (en) * | 2003-01-15 | 2004-08-05 | Board Of Regents, University Of Texas System | The use of c-raf inhibitors for the treatment of neurodegenerative diseases |
WO2004078756A2 (en) * | 2003-03-06 | 2004-09-16 | Eisai Co., Ltd. | Jnk inhibitors |
MXPA05012350A (es) * | 2003-05-20 | 2006-05-25 | Transtech Pharma Inc | Antagonistas rage como agentes para la amiloidosis inversa y enfermedades asociadas con la misma. |
EP1493438A1 (de) * | 2003-07-03 | 2005-01-05 | Bayer HealthCare AG | Inhibitoren des Vanilloid-Rezeptors (VR1) zur Behandlung von HIV-bedingten Schmerz |
EP1670787B1 (de) | 2003-09-11 | 2012-05-30 | iTherX Pharma, Inc. | Cytokininhibitoren |
US7662389B2 (en) * | 2003-12-17 | 2010-02-16 | Alcon, Inc. | Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
US20100113481A1 (en) * | 2003-12-17 | 2010-05-06 | Alcon Research, Ltd. | Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
GB0330042D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
MXPA06011327A (es) | 2004-03-30 | 2006-12-15 | Vertex Pharma | Azaindoles utiles como inhibidores de jak y otras proteinas cinasas. |
US8222293B2 (en) * | 2004-05-24 | 2012-07-17 | Regents of the University of Carolina | Treating learning deficits with inhibitors of Hmg CoA reductase |
HUE024953T2 (en) | 2004-08-23 | 2016-02-29 | Yeda Res & Dev | Peptide inhibitors to mediate stress responses |
CN101128453A (zh) * | 2005-02-28 | 2008-02-20 | 默克勒有限公司 | 2-亚磺酰基-和2-磺酰基-取代的咪唑衍生物和它们作为细胞因子抑制剂的用途 |
PE20100737A1 (es) * | 2005-03-25 | 2010-11-27 | Glaxo Group Ltd | Nuevos compuestos |
US7479558B2 (en) * | 2005-03-25 | 2009-01-20 | Glaxo Group Limited | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives |
US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
PE20070427A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas |
EP2559694A3 (de) | 2006-01-17 | 2013-04-03 | Vertex Pharmaceuticals, Inc. | Als Inhibitoren von Janus-Kinasen verwendbare Azaindole |
KR101464385B1 (ko) * | 2006-04-19 | 2014-11-21 | 노파르티스 아게 | 6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법 |
WO2007140358A2 (en) * | 2006-05-26 | 2007-12-06 | The Board Of Trustees Of The University Of Illinois | Treatment of polyglutamine-expansion neurodegenerative diseases |
GB0612026D0 (en) * | 2006-06-16 | 2006-07-26 | Smithkline Beecham Corp | New use |
EP2031965A4 (de) * | 2006-06-16 | 2010-06-30 | Glaxo Group Ltd | Neuartige verbindungen |
EP2032142A4 (de) * | 2006-06-16 | 2010-07-21 | Glaxo Group Ltd | Neuartige verbindungen |
ES2301380B1 (es) | 2006-08-09 | 2009-06-08 | Laboratorios Almirall S.A. | Nuevos derivados de 1,7-naftiridina. |
MX2009006700A (es) | 2006-12-21 | 2009-06-30 | Vertex Pharma | Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas. |
ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
ES2329639B1 (es) | 2007-04-26 | 2010-09-23 | Laboratorios Almirall S.A. | Nuevos derivados de 4,8-difenilpoliazanaftaleno. |
EP2108641A1 (de) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | Neue substituierte Spiro[Cycloalkyl-1,3'-indo]-2'(1'H)-on-Derivate und ihre Verwendung als p38 mitogen-activated Kinase Inhibitoren |
EP2113503A1 (de) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | Neue substituierte Indolin-2-on- Derivate und ihre Verwendung als p39 mitogen-activated Kinase Inhibitoren |
DE102008029072A1 (de) * | 2008-06-10 | 2009-12-17 | Lang, Florian, Prof. Dr.med. | Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen |
KR101204108B1 (ko) * | 2009-02-09 | 2012-11-22 | 주식회사 지엔티파마 | 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도 |
GEP20156325B (en) | 2009-06-17 | 2015-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
EP2322176A1 (de) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | Neue 7-Phenyl-[1,2,4]triazol[4,3-a]pyridin-3(2H)on-Derivate |
JP5682555B2 (ja) | 2010-04-28 | 2015-03-11 | 東レ株式会社 | アルツハイマー病の治療剤又は予防剤 |
US20120245188A1 (en) * | 2010-11-15 | 2012-09-27 | Translational Genomics Research Institute | Methods of treating memory loss and enhancing memory performance |
WO2012083117A1 (en) | 2010-12-16 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
EP3263127B1 (de) | 2011-05-23 | 2019-08-21 | Yeda Research and Development Co. Ltd | Verwendung einer akt-phosphorylierung als biomarker zur prognose neurodegenerativer erkrankungen und zur behandlung davon |
UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
WO2013086002A1 (en) * | 2011-12-05 | 2013-06-13 | Cellworks Research India Private Limited | Compositions, process of preparation of said compositions and method of treating cancer |
WO2013162027A1 (ja) * | 2012-04-27 | 2013-10-31 | 学校法人 慶應義塾 | 神経分化促進剤 |
EP2968322B1 (de) | 2013-03-15 | 2018-12-26 | The Trustees of Columbia University in the City of New York | Map-kinasemodulatoren und verwendungen davon |
PL3068776T3 (pl) | 2013-11-13 | 2019-10-31 | Vertex Pharma | Inhibitory replikacji wirusów grypy |
JP6618901B2 (ja) | 2013-11-13 | 2019-12-11 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インフルエンザウイルスの複製の阻害剤を調製する方法 |
EP3294717B1 (de) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Verfahren zur herstellung von inhibitoren der influenzavirenreplikation |
EP3294735B8 (de) | 2015-05-13 | 2022-01-05 | Vertex Pharmaceuticals Incorporated | Hemmer der influenzavirenreplikation |
US10702589B2 (en) * | 2016-10-04 | 2020-07-07 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Compositions and methods of treating neurological disorder and stress-induced conditions |
EP3615529A1 (de) | 2017-04-26 | 2020-03-04 | Basilea Pharmaceutica International AG | Verfahren zur herstellung von furazanbenzimidazolen und kristallinen formen davon |
CN116617224A (zh) * | 2023-05-04 | 2023-08-22 | 上海交通大学医学院附属瑞金医院 | OPN和p38 MAPK信号通路靶向调控剂在制备神经退行性疾病药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6147080A (en) * | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US6093742A (en) * | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
WO1999061039A2 (en) * | 1998-05-22 | 1999-12-02 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel composition for modulating ischemic cell death |
US6288089B1 (en) * | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
-
2000
- 2000-06-30 EP EP00948576A patent/EP1196167B1/de not_active Expired - Lifetime
- 2000-06-30 CA CA002373883A patent/CA2373883A1/en not_active Abandoned
- 2000-06-30 WO PCT/US2000/018385 patent/WO2001001986A1/en active IP Right Grant
- 2000-06-30 ES ES00948576T patent/ES2260033T3/es not_active Expired - Lifetime
- 2000-06-30 DE DE60027431T patent/DE60027431T2/de not_active Expired - Lifetime
- 2000-06-30 JP JP2001507478A patent/JP2003503456A/ja not_active Withdrawn
- 2000-06-30 AU AU62052/00A patent/AU777275B2/en not_active Ceased
- 2000-06-30 AT AT00948576T patent/ATE323482T1/de not_active IP Right Cessation
-
2002
- 2002-04-02 US US10/115,578 patent/US20030078274A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1196167B1 (de) | 2006-04-19 |
AU777275B2 (en) | 2004-10-07 |
WO2001001986A1 (en) | 2001-01-11 |
EP1196167A1 (de) | 2002-04-17 |
JP2003503456A (ja) | 2003-01-28 |
EP1196167A4 (de) | 2003-05-02 |
CA2373883A1 (en) | 2001-01-11 |
DE60027431T2 (de) | 2007-07-12 |
DE60027431D1 (de) | 2006-05-24 |
US20030078274A1 (en) | 2003-04-24 |
AU6205200A (en) | 2001-01-22 |
ES2260033T3 (es) | 2006-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60027431D1 (de) | Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten | |
ATE207356T1 (de) | Verwendung von tiagabin zur behandlung von schlafstörungen | |
ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
DE69936102D1 (de) | Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden | |
DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
ATE361752T1 (de) | Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen | |
ATE211129T1 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
DE69521620D1 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
ATE381935T1 (de) | Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen | |
EA200200847A1 (ru) | Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов | |
ATE365550T1 (de) | Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie | |
DE69403969T2 (de) | Levobupivacain nützlich zur behandlung von chronischen schmerzen | |
ATE198706T1 (de) | Polyamin-verbindungen zur behandlung von proliferativer erkrankungen | |
ATE375141T1 (de) | Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer | |
NO20052153L (no) | Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer. | |
DE69900847D1 (de) | Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten | |
DE60218153D1 (de) | Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges | |
ATE222491T1 (de) | Melatonin-derivate zur verwendung in der behandlung von schlafstörungen | |
DE69912304D1 (de) | Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen | |
DE59907195D1 (de) | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs | |
DE69432626D1 (de) | Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen | |
ATE294584T1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
ATE214605T1 (de) | Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs | |
ATE428470T1 (de) | Heilmittel zur behandlung von erkrankungen des sehnervs | |
DE69924284D1 (de) | Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |